Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Stock Information for Provention Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.